Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

UPDATE 1-Australia probes if blood clot case linked to AstraZeneca vaccine

Published 02/04/2021, 05:57 pm
Updated 02/04/2021, 06:00 pm
© Reuters.

(Adds more detail, quotes)

By Lidia Kelly

MELBOURNE, April 2 (Reuters) - Australia is investigating whether a blood clotting case recorded on Friday is related to the AstraZeneca (NASDAQ:AZN) coronavirus vaccine, a health official said, raising concern in a nation where most people are expected to receive the drugmaker's shot.

A 44-year-old man was admitted to a Melbourne hospital with clotting days after receiving the AstraZeneca AZN.L vaccine, suffering serious thrombosis and a low count of platelets, or blood cells that stop bleeding.

"Investigators have not at this time confirmed a causal link with the COVID-19 AstraZeneca vaccine, but investigations are ongoing," the deputy chief medical officer, Michael Kidd, told a televised briefing.

More was expected to be known on Saturday, he added.

On Thursday, Britain identified 30 cases of rare blood clot events following use of the vaccine, and several nations, including Canada, France, Germany and Spain, limited its use after similar reports. regulator the Therapeutic Goods Administration (TGA) has said previously the AstraZeneca vaccine was not tied to an increase in overall risk of blood clots, however.

In a statement on Friday, the Australian Technical Advisory Group on Immunisation said, "There is not a higher overall rate of relatively common types of blood clots (...) reported after COVID-19 vaccination."

Australia launched mass vaccinations for its 25 million people in February, with most expected to receive the University of Oxford/AstraZeneca vaccine. In late March, CSL Ltd CSL.AX began domestic production of 50 million doses.

Australia has been highly successful in curbing the virus with snap lockdowns, border closures and swift tracking, reporting just under 29,300 infections and 909 deaths.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

It has had troubles rolling out its vaccination program, however, missing a March target by about 3.3 million doses as states and the federal government bickered over the blame. supplies in the northeastern state of Queensland will end within days, health officials said on Friday, adding that they were uncertain about the next delivery. L1N2LV033

(Global vaccination tracker: https://graphics.reuters.com/world-coronavirus-tracker-and-maps/vaccination-rollout-and-access/)

(Interactive graphic tracking global spread of coronavirus: https://graphics.reuters.com/world-coronavirus-tracker-and-maps/)

<^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ FACTBOX-Latest on global spread of coronavirus

ID:nL8N2AB5TN Coronavirus: knowns and unknowns

https://reut.rs/2UHIgvz

FACTBOX-Worldwide coronavirus deaths exceed 2.9 mln

ID:nL4N2AY3AS

^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.